Jian‐Ping Li

Jian‐Ping Li

Auto-generated profile, based on publicly available information

Jian‐Ping Li

Transfusion Medicine Institute, Liaoning Blood Center Shenyang China

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2021 in Cell Proliferation
Verified
Journal Article
Open access
PDF file
WLWensi Liu
Wensi Liu
HTHaichao Tang
Haichao Tang
LLLuanfeng Li
Luanfeng Li
XWXiangyi Wang
Xiangyi Wang
ZYZhaojin Yu
Zhaojin Yu
JLJianping Li
Jianping Li
The peptide‐based therapeutic cancer vaccines have attracted enormous attention in recent years as one of the effective treatments of tumour immunotherapy. Most of peptide‐based vaccines are based on epitope peptides stimulating CD8+ T cells or CD4+ T helper cells to target tumour‐associated antigens (TAAs) or tumour‐specific antigens (TSAs). Some adjuvants and nanomaterials have been exploited to optimize the efficiency of immune response of the epitope peptide to improve its clinical application. At present, numerous peptide‐based therapeutic cancer vaccines have been developed and achieved significant clinical benefits. Similarly, the combination of peptide‐based vaccines and other therapies has demonstrated a superior efficacy in improving anti‐cancer activity. We delve deeper into the choices of targets, design and screening of epitope peptides, clinical efficacy and adverse events of peptide‐based vaccines, and strategies combination of peptide‐based therapeutic cancer vaccines and other therapies. The review will provide a detailed overview and basis for future clinical application of peptide‐based therapeutic cancer vaccines.

2 August 2018 in HLA
Verified
Journal Article
Closed access
PDF file
YHY. He
Y. He
JLJ. Li
J. Li
WMW. Mao
W. Mao
DZD. Zhang
D. Zhang
MLM. Liu
M. Liu
DDD. Du
D. Du

30 September 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
XZXiao-Yang Zhou
Xiao-Yang Zhou
FZFa-Ming Zhu
Fa-Ming Zhu
JLJian-Ping Li
Jian-Ping Li
WMWei Mao
Wei Mao
DZDe-Mei Zhang
De-Mei Zhang
JCJian-Ping Cai
Jian-Ping Cai
Allogeneic hematopoietic stem cell transplantation is a widely used and effective therapy for hematopoietic malignant diseases and numerous other disorders. High-resolution human leukocyte antigen (HLA) haplotype frequency distributions not only facilitate individual donor searches but also determine the probability with which a particular patient can find HLA-matched donors in a registry. The frequencies of the HLA-A, -B, -C, -DRB1, and -DQB1 alleles and haplotypes were estimated among 169,995 Chinese volunteers using the sequencing-based typing (SBT) method. Totals of 191 HLA-A, 244 HLA-B, 146 HLA-C, 143 HLA-DRB1 and 47 HLA-DQB1 alleles were observed, which accounted for 6.98%, 7.06%, 6.46%, 9.11% and 7.91%, respectively, of the alleles in each locus in the world (IMGT 3.16 Release, Apr. 2014). Among the 100 most common haplotypes from the 169,995 individuals, nine distinct haplotypes displayed significant regionally specific distributions. Among these, three were predominant in the South China region (i.e., the 20th, 31st, and 81sthaplotypes), another three were predominant in the Southwest China region (i.e., the 68th, 79th, and 95th haplotypes), one was predominant in the South and Southwest China regions (the 18th haplotype), one was relatively common in the Northeast and North China regions (the 94th haplotype), and one was common in the Northeast, North and Northwest China (the 40th haplotype). In conclusion, this is the first to analyze high-resolution HLA diversities across the entire country of China, based on a detailed and complete data set that covered 31 provinces, autonomous regions, and municipalities. Specifically, we also evaluated the HLA matching probabilities within and between geographic regions and analyzed the regional differences in the HLA diversities in China. We believe that the data presented in this study might be useful for unrelated HLA-matched donor searches, donor registry planning, population genetic studies, and anthropogenesis studies.

28 August 2012 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
CLChangqing Li
Changqing Li
XXXiaopu Xiao
Xiaopu Xiao
HYHuimin Yin
Huimin Yin
MHMiao He
Miao He
JLJianping Li
Jianping Li
WLWuping Li
Wuping Li
In China, high prevalence of HBV and HCV parallels with the growing epidemic of syphilis and HIV in the general population poses a great threat to blood safety. This study investigated the prevalence of serologic markers for transfusion transmissible infections (TTIs) among four Chinese blood centers.

1 May 1996 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SISadahiko Iwamoto
Sadahiko Iwamoto
JLJianping Li
Jianping Li
NSNaoya Sugimoto
Naoya Sugimoto
HOHiroshi Okuda
Hiroshi Okuda
EKEiji Kajii
Eiji Kajii

28 April 2021 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
ZYZhaojin Yu
Zhaojin Yu
WLWensi Liu
Wensi Liu
YHYing He
Ying He
MSMingli Sun
Mingli Sun
JYJiankun Yu
Jiankun Yu
MWMinjie Wei
Minjie Wei
Background: CD8+T cell-mediated adaptive cellular immunity and natural killer (NK) cell-mediated innate immunity both play important roles in tumour immunity. This study aimed to develop therapeutic tumour vaccines based on double-activation of CD8+T and NK cells.Methods: The immune Epitope database, Molecular Operating Environment software, and enzyme-linked immunosorbent assay were used for epitope identification. Flow cytometry, confocal microscopy, UPLC-QTOF-MS, and RNA-seq were utilized for evaluating immunity of PBMC-derived DCs, CD8+T or NK cells and related pathways.HLA-A2.1transgenic mice combined with immunologically reconstituted tumour-bearing mice were used to examine the antitumour effect and safety of epitope vaccines.Results: We identified novel HLA-A2.1-restricted extracellular matrix protein 1(ECM1)-derived immunodominant epitopes in which LA induced a potent immune response. We also found that LA-loaded DCs upregulated the frequency of CD3+/CD8+T cells, CD45RO+/CD69+activated memory T cells, and CD3−/CD16+/CD56+NK cells. We demonstrated cytotoxic granule release of LA/DC-CTLs or LA/DC-NK cells and cytotoxicity against tumour cells and microtissue blocks via the predominant IFN-γ/perforin/granzyme B cell death pathway. Further investigating the mechanism of LA-mediated CD8+T activation, we found that LA could be internalized into DCs through phagocytosis and then formed a LA-MHC-I complex presented onto the DC surface for recognition of the T cell receptor to upregulate Zap70 phosphorylation levels to further activate CD8+T cells by DC-CTL interactions. In addition, LA-mediated DC-NK crosstalk through stimulation of the TLR4-p38 MAPK pathway increased MICA/B expression on DCs to interact with NKG2D for NK activation. Promisingly, LA could activate CD8+T cells and NK cells simultaneously via interacting with DCs to suppress tumours in vivo. Moreover, the safety of LA was confirmed.Conclusions: LA-induced immune antitumour activity through DC cross-activation with CD8+T and NK cells, which demonstrated proof-of-concept evidence for the capability and safety of a novel therapeutic tumour vaccine.